STOCK TITAN

[8-K] Serina Therapeutics, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

FormFactor Inc. (FORM) has filed a Form 144 notice indicating an intended insider sale of up to 4,000 common shares through Morgan Stanley Smith Barney on or about 01 Jul 2025. Based on the filing’s stated aggregate market value of $136,106.80, the planned transaction represents roughly 0.005 % of the company’s 77,076,642 shares outstanding, implying minimal ownership dilution or trading-volume impact.

The seller, identified in the past-sales table as Mike Slessor, acquired the shares as performance stock on 19 Jul 2022. The document notes no gift status or non-cash consideration. Within the preceding three months, the same individual sold 8,000 shares in two tranches (01 May 2025 and 02 Jun 2025) for combined gross proceeds of $246,188.80. Adding the upcoming sale would bring the rolling three-month total to 12,000 shares.

The filing contains the standard representation that the seller is not in possession of undisclosed material adverse information and provides no indication of additional planned transactions beyond the stated amount. Given the modest size relative to market float and the routine nature of a Rule 144 filing, immediate financial impact appears limited; however, continued insider selling can sometimes influence investor sentiment.

FormFactor Inc. (FORM) ha presentato un avviso Form 144 che indica la vendita prevista da parte di un insider di fino a 4.000 azioni ordinarie tramite Morgan Stanley Smith Barney intorno al 01 luglio 2025. In base al valore di mercato aggregato dichiarato nel documento, pari a 136.106,80 $, l’operazione rappresenta circa lo 0,005 % delle 77.076.642 azioni in circolazione, implicando un impatto minimo su diluizione della proprietà o sul volume di scambi.

Il venditore, identificato nella tabella delle vendite precedenti come Mike Slessor, ha acquisito queste azioni come performance stock il 19 luglio 2022. Il documento specifica che non si tratta di un dono né di una transazione in contanti non monetaria. Nei tre mesi precedenti, la stessa persona ha venduto 8.000 azioni in due tranche (01 maggio 2025 e 02 giugno 2025) per un ricavo lordo complessivo di 246.188,80 $. Con la vendita imminente, il totale delle azioni vendute negli ultimi tre mesi salirebbe a 12.000.

Il modulo contiene la dichiarazione standard che il venditore non è in possesso di informazioni materiali sfavorevoli non divulgate e non indica ulteriori vendite pianificate oltre a quelle dichiarate. Considerando la dimensione modesta rispetto al flottante di mercato e la natura ordinaria di una comunicazione ai sensi della Regola 144, l’impatto finanziario immediato sembra limitato; tuttavia, vendite continue da parte degli insider possono talvolta influenzare il sentiment degli investitori.

FormFactor Inc. (FORM) ha presentado un aviso Form 144 indicando una venta interna prevista de hasta 4.000 acciones comunes a través de Morgan Stanley Smith Barney alrededor del 01 de julio de 2025. Según el valor de mercado agregado declarado en el documento, de $136,106.80, la transacción representa aproximadamente el 0,005 % de las 77,076,642 acciones en circulación, lo que implica una dilución mínima de la propiedad o impacto en el volumen de negociación.

El vendedor, identificado en la tabla de ventas anteriores como Mike Slessor, adquirió las acciones como acciones de desempeño el 19 de julio de 2022. El documento señala que no se trata de un regalo ni de una contraprestación no monetaria. En los tres meses anteriores, la misma persona vendió 8,000 acciones en dos tramos (01 de mayo de 2025 y 02 de junio de 2025) por un ingreso bruto combinado de $246,188.80. Sumando la venta próxima, el total en tres meses sería de 12,000 acciones.

El aviso contiene la representación estándar de que el vendedor no posee información adversa material no divulgada y no indica transacciones adicionales planificadas más allá de la cantidad declarada. Dado el tamaño modesto en relación con el flotante del mercado y la naturaleza rutinaria de una presentación bajo la Regla 144, el impacto financiero inmediato parece limitado; sin embargo, la venta continua por parte de insiders puede influir en el sentimiento de los inversores.

FormFactor Inc. (FORM)는 Morgan Stanley Smith Barney를 통해 2025년 7월 1일경 최대 4,000주 보통주 내부자 매각을 의도하는 Form 144 신고서를 제출했습니다. 신고서에 명시된 총 시장가치 $136,106.80를 기준으로, 이번 거래는 회사의 77,076,642주 발행 주식 중 약 0.005 %에 해당하여 소유권 희석이나 거래량에 미치는 영향이 미미함을 시사합니다.

판매자는 과거 매도 내역 표에 Mike Slessor로 확인되며, 2022년 7월 19일에 성과 주식(performance stock)으로 주식을 취득했습니다. 문서에는 증여 상태나 비현금 대가가 없음을 명시하고 있습니다. 최근 3개월 내에 동일인이 2025년 5월 1일과 6월 2일 두 차례에 걸쳐 총 8,000주를 매도하여 총 매출액 $246,188.80을 기록했습니다. 이번 매각이 추가되면 최근 3개월 총 매도 주식은 12,000주가 됩니다.

신고서에는 판매자가 미공개 중대한 불리한 정보를 보유하지 않았다는 표준 진술이 포함되어 있으며, 명시된 금액 외 추가 계획된 거래는 없음을 나타냅니다. 시장 유동성 대비 규모가 작고 Rule 144 신고의 일상적인 성격을 고려할 때 즉각적인 재무 영향은 제한적일 것으로 보이나, 지속적인 내부자 매도는 투자자 심리에 영향을 줄 수 있습니다.

FormFactor Inc. (FORM) a déposé un avis Form 144 indiquant la vente prévue par un initié de jusqu’à 4 000 actions ordinaires via Morgan Stanley Smith Barney aux alentours du 1er juillet 2025. Selon la valeur marchande agrégée déclarée dans le dépôt, s’élevant à 136 106,80 $, la transaction représente environ 0,005 % des 77 076 642 actions en circulation, impliquant une dilution minimale de la propriété ou un impact limité sur le volume des échanges.

Le vendeur, identifié dans le tableau des ventes passées comme Mike Slessor, a acquis les actions en tant que performance stock le 19 juillet 2022. Le document précise qu’il ne s’agit ni d’un don ni d’une contrepartie non monétaire. Au cours des trois mois précédents, cette même personne a vendu 8 000 actions en deux tranches (1er mai 2025 et 2 juin 2025) pour un produit brut total de 246 188,80 $. Avec la vente à venir, le total sur trois mois atteindrait 12 000 actions.

Le dépôt contient la déclaration standard selon laquelle le vendeur ne détient pas d’informations matérielles défavorables non divulguées et ne prévoit pas d’autres transactions au-delà du montant indiqué. Étant donné la taille modeste par rapport au flottant du marché et la nature routinière d’un dépôt conforme à la règle 144, l’impact financier immédiat semble limité ; toutefois, des ventes répétées par des initiés peuvent parfois influencer le sentiment des investisseurs.

FormFactor Inc. (FORM) hat eine Form 144-Mitteilung eingereicht, die einen geplanten Insider-Verkauf von bis zu 4.000 Stammaktien über Morgan Stanley Smith Barney um den 01. Juli 2025 anzeigt. Basierend auf dem im Formular angegebenen aggregierten Marktwert von 136.106,80 $ entspricht die geplante Transaktion etwa 0,005 % der insgesamt 77.076.642 ausstehenden Aktien des Unternehmens, was auf eine minimale Verwässerung des Eigentums oder einen geringen Einfluss auf das Handelsvolumen hindeutet.

Der Verkäufer, in der Tabelle der vergangenen Verkäufe als Mike Slessor aufgeführt, erwarb die Aktien am 19. Juli 2022 als Performance-Aktien. Im Dokument wird angegeben, dass es sich weder um eine Schenkung noch um eine nicht-monetäre Gegenleistung handelt. Innerhalb der letzten drei Monate hat dieselbe Person 8.000 Aktien in zwei Tranchen (01. Mai 2025 und 02. Juni 2025) verkauft und dabei einen Bruttobetrag von 246.188,80 $ erzielt. Mit dem bevorstehenden Verkauf würde die Summe der letzten drei Monate auf 12.000 Aktien steigen.

Die Einreichung enthält die standardmäßige Erklärung, dass der Verkäufer nicht im Besitz nicht veröffentlichter wesentlicher negativer Informationen ist und weist keine weiteren geplanten Transaktionen über den angegebenen Betrag hinaus aus. Angesichts der geringen Größe im Verhältnis zum Streubesitz und der routinemäßigen Natur einer Regel-144-Meldung erscheint die unmittelbare finanzielle Auswirkung begrenzt; dennoch kann fortgesetzter Insider-Verkauf manchmal die Anlegerstimmung beeinflussen.

Positive
  • Regulatory compliance: Timely Form 144 filing demonstrates transparency and adherence to SEC insider-sale rules.
Negative
  • Continued insider selling: Aggregate 12,000 shares sold or planned within three months could be perceived as waning insider confidence, despite small relative size.

Insights

TL;DR: Small insider sale (0.005 % float) is routine; sentiment risk minor, fundamental impact negligible.

The filing covers 4,000 shares worth about $136k, following two earlier 4,000-share tranches. Even aggregated, 12,000 shares equal only ~0.016 % of outstanding stock, so supply overhang is immaterial. Because the shares derive from performance awards, the sale may simply reflect personal diversification rather than adverse views on FormFactor’s outlook. No pricing details beyond market value are disclosed, and nothing in the notice suggests undisclosed operational issues. From a valuation standpoint, therefore, I see neutral financial impact; the primary takeaway is a potential marginal sentiment headwind if investors focus on the insider activity.

TL;DR: Filing signals compliance and transparency; repeated sales could draw light governance scrutiny.

Rule 144 notices are expected when insiders dispose of restricted stock. The prompt disclosure underscores adherence to SEC requirements, which is governance-positive. Nonetheless, three sales within three months may trigger investor questions about executive alignment, especially absent offsetting insider purchases. The percentage sold is immaterial to control, so no governance red flags arise. Overall, the event is non-impactful but worth monitoring if sales accelerate.

FormFactor Inc. (FORM) ha presentato un avviso Form 144 che indica la vendita prevista da parte di un insider di fino a 4.000 azioni ordinarie tramite Morgan Stanley Smith Barney intorno al 01 luglio 2025. In base al valore di mercato aggregato dichiarato nel documento, pari a 136.106,80 $, l’operazione rappresenta circa lo 0,005 % delle 77.076.642 azioni in circolazione, implicando un impatto minimo su diluizione della proprietà o sul volume di scambi.

Il venditore, identificato nella tabella delle vendite precedenti come Mike Slessor, ha acquisito queste azioni come performance stock il 19 luglio 2022. Il documento specifica che non si tratta di un dono né di una transazione in contanti non monetaria. Nei tre mesi precedenti, la stessa persona ha venduto 8.000 azioni in due tranche (01 maggio 2025 e 02 giugno 2025) per un ricavo lordo complessivo di 246.188,80 $. Con la vendita imminente, il totale delle azioni vendute negli ultimi tre mesi salirebbe a 12.000.

Il modulo contiene la dichiarazione standard che il venditore non è in possesso di informazioni materiali sfavorevoli non divulgate e non indica ulteriori vendite pianificate oltre a quelle dichiarate. Considerando la dimensione modesta rispetto al flottante di mercato e la natura ordinaria di una comunicazione ai sensi della Regola 144, l’impatto finanziario immediato sembra limitato; tuttavia, vendite continue da parte degli insider possono talvolta influenzare il sentiment degli investitori.

FormFactor Inc. (FORM) ha presentado un aviso Form 144 indicando una venta interna prevista de hasta 4.000 acciones comunes a través de Morgan Stanley Smith Barney alrededor del 01 de julio de 2025. Según el valor de mercado agregado declarado en el documento, de $136,106.80, la transacción representa aproximadamente el 0,005 % de las 77,076,642 acciones en circulación, lo que implica una dilución mínima de la propiedad o impacto en el volumen de negociación.

El vendedor, identificado en la tabla de ventas anteriores como Mike Slessor, adquirió las acciones como acciones de desempeño el 19 de julio de 2022. El documento señala que no se trata de un regalo ni de una contraprestación no monetaria. En los tres meses anteriores, la misma persona vendió 8,000 acciones en dos tramos (01 de mayo de 2025 y 02 de junio de 2025) por un ingreso bruto combinado de $246,188.80. Sumando la venta próxima, el total en tres meses sería de 12,000 acciones.

El aviso contiene la representación estándar de que el vendedor no posee información adversa material no divulgada y no indica transacciones adicionales planificadas más allá de la cantidad declarada. Dado el tamaño modesto en relación con el flotante del mercado y la naturaleza rutinaria de una presentación bajo la Regla 144, el impacto financiero inmediato parece limitado; sin embargo, la venta continua por parte de insiders puede influir en el sentimiento de los inversores.

FormFactor Inc. (FORM)는 Morgan Stanley Smith Barney를 통해 2025년 7월 1일경 최대 4,000주 보통주 내부자 매각을 의도하는 Form 144 신고서를 제출했습니다. 신고서에 명시된 총 시장가치 $136,106.80를 기준으로, 이번 거래는 회사의 77,076,642주 발행 주식 중 약 0.005 %에 해당하여 소유권 희석이나 거래량에 미치는 영향이 미미함을 시사합니다.

판매자는 과거 매도 내역 표에 Mike Slessor로 확인되며, 2022년 7월 19일에 성과 주식(performance stock)으로 주식을 취득했습니다. 문서에는 증여 상태나 비현금 대가가 없음을 명시하고 있습니다. 최근 3개월 내에 동일인이 2025년 5월 1일과 6월 2일 두 차례에 걸쳐 총 8,000주를 매도하여 총 매출액 $246,188.80을 기록했습니다. 이번 매각이 추가되면 최근 3개월 총 매도 주식은 12,000주가 됩니다.

신고서에는 판매자가 미공개 중대한 불리한 정보를 보유하지 않았다는 표준 진술이 포함되어 있으며, 명시된 금액 외 추가 계획된 거래는 없음을 나타냅니다. 시장 유동성 대비 규모가 작고 Rule 144 신고의 일상적인 성격을 고려할 때 즉각적인 재무 영향은 제한적일 것으로 보이나, 지속적인 내부자 매도는 투자자 심리에 영향을 줄 수 있습니다.

FormFactor Inc. (FORM) a déposé un avis Form 144 indiquant la vente prévue par un initié de jusqu’à 4 000 actions ordinaires via Morgan Stanley Smith Barney aux alentours du 1er juillet 2025. Selon la valeur marchande agrégée déclarée dans le dépôt, s’élevant à 136 106,80 $, la transaction représente environ 0,005 % des 77 076 642 actions en circulation, impliquant une dilution minimale de la propriété ou un impact limité sur le volume des échanges.

Le vendeur, identifié dans le tableau des ventes passées comme Mike Slessor, a acquis les actions en tant que performance stock le 19 juillet 2022. Le document précise qu’il ne s’agit ni d’un don ni d’une contrepartie non monétaire. Au cours des trois mois précédents, cette même personne a vendu 8 000 actions en deux tranches (1er mai 2025 et 2 juin 2025) pour un produit brut total de 246 188,80 $. Avec la vente à venir, le total sur trois mois atteindrait 12 000 actions.

Le dépôt contient la déclaration standard selon laquelle le vendeur ne détient pas d’informations matérielles défavorables non divulguées et ne prévoit pas d’autres transactions au-delà du montant indiqué. Étant donné la taille modeste par rapport au flottant du marché et la nature routinière d’un dépôt conforme à la règle 144, l’impact financier immédiat semble limité ; toutefois, des ventes répétées par des initiés peuvent parfois influencer le sentiment des investisseurs.

FormFactor Inc. (FORM) hat eine Form 144-Mitteilung eingereicht, die einen geplanten Insider-Verkauf von bis zu 4.000 Stammaktien über Morgan Stanley Smith Barney um den 01. Juli 2025 anzeigt. Basierend auf dem im Formular angegebenen aggregierten Marktwert von 136.106,80 $ entspricht die geplante Transaktion etwa 0,005 % der insgesamt 77.076.642 ausstehenden Aktien des Unternehmens, was auf eine minimale Verwässerung des Eigentums oder einen geringen Einfluss auf das Handelsvolumen hindeutet.

Der Verkäufer, in der Tabelle der vergangenen Verkäufe als Mike Slessor aufgeführt, erwarb die Aktien am 19. Juli 2022 als Performance-Aktien. Im Dokument wird angegeben, dass es sich weder um eine Schenkung noch um eine nicht-monetäre Gegenleistung handelt. Innerhalb der letzten drei Monate hat dieselbe Person 8.000 Aktien in zwei Tranchen (01. Mai 2025 und 02. Juni 2025) verkauft und dabei einen Bruttobetrag von 246.188,80 $ erzielt. Mit dem bevorstehenden Verkauf würde die Summe der letzten drei Monate auf 12.000 Aktien steigen.

Die Einreichung enthält die standardmäßige Erklärung, dass der Verkäufer nicht im Besitz nicht veröffentlichter wesentlicher negativer Informationen ist und weist keine weiteren geplanten Transaktionen über den angegebenen Betrag hinaus aus. Angesichts der geringen Größe im Verhältnis zum Streubesitz und der routinemäßigen Natur einer Regel-144-Meldung erscheint die unmittelbare finanzielle Auswirkung begrenzt; dennoch kann fortgesetzter Insider-Verkauf manchmal die Anlegerstimmung beeinflussen.

0001708599false00017085992025-07-012025-07-01

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): July 1, 2025
Serina Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware1-3851982-1436829
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
601 Genome Way, Suite 2001
Huntsville, Alabama 35806
(Address of principal executive offices)
(256) 327-9630
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of exchange on which registered
Common Stock, par value $0.0001 per shareSERNYSE American
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o





Item 5.08. Shareholder Director Nominations

The information set forth under Item 8.01 regarding the deadline for submitting proposals for director nominations is incorporated herein by reference.

Item 7.01.      Regulation FD Disclosure
Attached hereto as Exhibit 99.1 is a press release dated July 1, 2025, for Serina Therapeutics, Inc. (the “Serina”).
The information in this Item 7.01 is being furnished, not filed, pursuant to Regulation FD. Accordingly, the information in this report will not be incorporated by reference into any registration statement filed by Serina under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this report is not intended to, and does not, constitute a determination or admission by Serina that the information in this report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of Serina.
Item 8.01. Other Events.
Serina has set November 7, 2025, as the date for its 2025 annual meeting of stockholders (the “Annual Meeting”). The time and location of the Annual Meeting will be set forth in Serina’s definitive proxy statement for the Annual Meeting to be filed with the Securities and Exchange Commission (the “SEC”).
Because the date of the Annual Meeting represents a change of more than 30 days from the anniversary of Serina’s 2024 annual meeting of stockholders, the deadline for stockholder proposals to be submitted pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), for inclusion in Serina’ proxy materials for the Annual Meeting will be 5:00 p.m. (Central Time) on Friday, August 15, 2025, which Serina’s Board of Directors has determined to be a reasonable period of time before Serina expects to begin to print and send its proxy materials for the Annual Meeting. Stockholder proposals submitted in accordance with Rule 14a-8 of the Exchange Act must also comply with the remaining requirements of Rule 14a 8 in order to be included in the proxy materials for the Annual Meeting.
Stockholder proposals and director nominations submitted pursuant to Serina’s Amended and Restated Bylaws for consideration at the Annual Meeting must be submitted in writing and must be received by the Corporate Secretary at Serina’s principal executive offices at Serina Therapeutics, Inc., 601 Genome Way, Suite 2001, Huntsville, Alabama 35806, no earlier than July 10, 2025, and no later than August 9, 2025, in order to be considered timely. Stockholder proposals outside of Rule 14a-8 of the Exchange Act and director nominations must also comply with the requirements contained in Section 3.2 of Serina’s Amended and Restated Bylaws in order to be considered at the Annual Meeting. Stockholders are urged to read the complete text of Serina’s Amended and Restated Bylaws for complete information regarding submission.
Item 9.01    Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Number
Description
99.1
Press Release, dated July 1, 2025, issued by Serina Therapeutics, Inc.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SERINA THERAPEUTICS, INC.
Date: July 1, 2025
By:/s/ Steve Ledger
Chief Executive Officer

FAQ

How many FormFactor (FORM) shares are covered by the new Form 144 filing?

The notice covers 4,000 common shares.

What is the approximate market value of the shares to be sold?

The aggregate market value stated is $136,106.80.

When is the planned sale date for the Form 144 shares?

The filer lists an approximate sale date of 01 July 2025.

What percentage of FormFactor’s outstanding shares does 4,000 shares represent?

Roughly 0.005 % of the 77,076,642 shares outstanding.

What insider sales occurred in the prior three months?

The same seller disposed of 8,000 shares in May and June 2025 for total proceeds of $246,188.80.

Who is the broker executing the proposed transaction?

The broker is Morgan Stanley Smith Barney LLC, Executive Financial Services, New York.
Serina Therapeutics

NYSE:SER

SER Rankings

SER Latest News

SER Latest SEC Filings

SER Stock Data

58.77M
3.60M
65.36%
3.4%
0.31%
Biotechnology
Pharmaceutical Preparations
Link
United States
HUNTSVILLE